Financial Performance - Operating revenue fell by 31.66% to CNY 131,807,335.11 year-on-year[5] - Net profit attributable to shareholders decreased by 219.32% to a loss of CNY 10,550,402.49[5] - Basic and diluted earnings per share both reported a loss of CNY 0.02, a decrease of 150% compared to the previous year[5] - Operating revenue for Q1 2020 was CNY 131,807,335.11, a decrease of 31.66% compared to CNY 192,878,575.35 in the previous period, primarily due to a decline in outpatient visits caused by the pandemic[12] - Net profit for Q1 2020 was a loss of ¥11,528,058.65, compared to a profit of ¥13,596,802.12 in Q1 2019, indicating a significant decline[26] - The company's gross profit margin for Q1 2020 was approximately -14.5%, down from a positive margin in Q1 2019[25] Cash Flow - Cash flow from operating activities showed a significant decline of 180.82%, resulting in a negative cash flow of CNY 4,667,291.75[5] - Cash received from operating activities increased by 111.53% to CNY 9,549,884.53, indicating improved cash flow from operations[13] - In Q1 2020, the company reported a net cash flow from operating activities of -4,667,291.75 RMB, a decrease from 5,775,207.01 RMB in Q1 2019, indicating a decline of approximately 181% year-over-year[33] - Total cash inflow from operating activities was 148,378,096.21 RMB, down 16.4% from 177,575,194.25 RMB in the same period last year[33] - Cash outflow from operating activities totaled 153,045,387.96 RMB, a decrease of 10.9% from 171,799,987.24 RMB in Q1 2019[33] Assets and Liabilities - Total assets decreased by 0.61% to CNY 2,071,718,178.25 compared to the end of the previous year[5] - Current liabilities increased from ¥655,015,544.37 to ¥709,174,430.19, an increase of about 8.3%[20] - Non-current liabilities decreased from ¥356,667,015.05 to ¥301,291,665.65, a reduction of approximately 15.5%[20] - Total liabilities remained relatively stable, decreasing slightly from ¥1,011,682,559.42 to ¥1,010,466,095.84[20] - Total current assets decreased slightly from ¥694,990,673.17 to ¥676,180,597.10, a decline of about 2.6%[20] Shareholder Information - The number of shareholders reached 5,904, with the top ten shareholders holding a total of 36.20% of the shares[9] - The company's equity attributable to shareholders decreased from ¥872,085,560.42 to ¥864,750,735.27, a decline of about 0.4%[20] Government Support and Subsidies - The company received government subsidies amounting to CNY 1,369,828.53 during the reporting period[8] Other Financial Metrics - The weighted average return on equity dropped by 2.22 percentage points to -0.84%[5] - Research and development expenses increased to ¥5,609,841.33 in Q1 2020, up 27% from ¥4,418,752.74 in Q1 2019[25] - The company reported an investment income of ¥2,435,959.08 in Q1 2020, with no corresponding figure in Q1 2019[26] - Other comprehensive income for Q1 2020 was a loss of ¥27,464.76, compared to a loss of ¥1,370,735.69 in Q1 2019[27] Legal and Compliance Matters - The company plans to pursue legal action against a party for compensation related to unmet performance commitments from a previous acquisition[14] - The company is in the process of a non-public stock issuance, which has not yet been completed as of the report date[16] - The company is set to implement new revenue and leasing standards starting January 1, 2020, which may impact future financial reporting[44]
济民医疗(603222) - 2020 Q1 - 季度财报